Person: TEZCAN, SONGÜL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
TEZCAN
First Name
SONGÜL
Name
4 results
Search Results
Now showing 1 - 4 of 4
Publication Open Access The role of the clinical pharmacist in patient education and monitoring of patients under warfarin treatment(MARMARA UNIV, 2019-11-15) SANCAR, MESUT; Izzettin, Fikret Vehbi; Celik, Sevda; Acar, Rezzan Deniz; Tezcan, Songul; Aksoy, Nilay; Bektay, Muhammed Yunus; Sancar, MesutThis study was carried out on patients who were under anticoagulation treatment with warfarin, at the outpatient cardiology clinic. The aim was to determine the effectiveness of pharmacist consultation, education, and intervention on each patient's therapeutic results. A cross-sectional randomized trial has been done. Twenty-five patients were included in the study. The Oral Anticoagulation Knowledge (OAK) Test, Short Form-36 (SF-36) and Duke Anticoagulation Satisfaction Scale (DASS) were applied. Patients resumed their routine anticoagulation treatment and INR and complications were recorded during the study. Additionally, patients received patient education, consultation on lifestyle and anticoagulant usage issues from a pharmacist. The same tests were applied again to the patients on the 90th day of the study and the results were compared with the initial test. Maintenance of INR within the target range and complication rates were compared before and after the intervention. Pre-test and post-test results of the patients revealed statistically significant improvements on the physical and mental score components of the SF-36 (p = 0.001; p = 0.001), OAK test scores (p <= 0.001) and the (negative) limitations and burdens and positive effects components of the DASS (p = 0.005; p < 0.001; p = 0.001). The successful maintenance of INR within target range was significantly higher (p = 0.027). The positive effects of pharmacist consultation and education on therapeutic results were demonstrated.Publication Open Access Erişkin kemik iliği transplantasyon ünitesinde potansiyel ilaç etkileşimlerinin belirlenmesi - prospektif çalışma(2023-01-01) TEZCAN, SONGÜL; Öztürk G. S., Ratip S., TEZCAN S.Objective: Bone marrow treatment (BMT) is a long and complicated process with multiple drug use can lead to drug-drug interactions. The aim of our study is to evaluate potential drug interactions (PDIs) in patients hospitalized in the adult bone marrow transplantation unit. Material and Method: This was a prospective and descriptive study conducted in an adult BMT unit in a private hospital in Turkey between January-June 2021. Sociodemogphrapics of the patients were recorded. PDIs were analyzed via Medscape and Lexicomp drug interaction checker. SPSS 15 was used for analysis. Result and Discussion: Of 40 patients 22 (55%) were male and the mean age was 46. Most of the patients were diagnosed with multiple myeloma (35%) and 58% of the patients had at least one comorbid disease. The number of PDIs detected in the Lexicomp database was statistically higher than in the Medscape database (299 vs 244; p<0.05). More PDIS were found in patients with concomitant disease than in patients without (p<0.05). The number of comorbid diseases was found to be higher in this population. Additionally, the number of PDIs was found to be high. We think that clinical pharmacists have an important role in patient monitoring and management of PDIs in BMT unitsPublication Open Access Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer(BMJ PUBLISHING GROUP, 2018-03) SANCAR, MESUT; Tezcan, Songul; Izzettin, Fikret Vehbi; Sancar, Mesut; Turhal, Nazim Serdar; Yumuk, Perran FuldenObjective To determine and evaluate the pharmaceutical care needs and quality of life of patients with colorectal cancer. Methods 36 Patients with colorectal cancer eligible for chemotherapy after surgery were included in the study. The patients were followed up during 3 courses of chemotherapy and individual pharmaceutical care plans were developed. The quality of life of patients was evaluated before and after the third course of chemotherapy. Results The incidence of drug-related problems (DRPs) in chemotherapy-treated patients was reduced in the 3rd course as compared with 1st course (63.9% vs 75%, respectively; n = 36; p > 0.05). The clinical oncology pharmacist gave 147 recommendations to patients, which were followed in 98% (n = 144) of cases. 91.7% (n = 132) of the recommendations of clinical oncology pharmacists solved the drug-related problems; however, the remaining 8.3% (n = 12) did not solve the problems and the patients were referred to a doctor for further investigations. The symptom-related quality of life of patients related to anaemia, diarrhoea and neurotoxicity was reduced after the third course of chemotherapy (p < 0.05). Conclusions The pharmaceutical care provided by the clinical oncology pharmacist has an important role in the identification and resolution of DRPs. Evaluation of symptom-related quality of life is important for the monitoring of patients receiving chemotherapy.Publication Open Access Are there any potential drug-drug interactions with oral inhaler medications?: A retrospective study(2024-06-01) TEZCAN, SONGÜL; TEZCAN S., YABAN N.Background: Oral inhaler medications (OIMs) are widely used for many respiratory diseases. Although OIMs have minimal systemic effects, they may cause potential drug-drug interactions (pDDIs). Objectives: This study aims to evaluate drug interactions in patients using OIMs. Methods: This retrospective, and descriptive study was conducted in a community pharmacy in Istanbul (Turkey) between January 1, andMay 312,021. Prescriptions of all asthma and COPD patients aged 18 and over on the specified date were included in the study. Data were collected from the pharmacy information system. Sociodemograhic characteristics were recorded. pDDIs were analyzed via Medscape and Lexicomp drug interaction checker databases. Significant (monitor closely), Serious (use alternative), Contraindicated categories in the Medscape database and D (consider treatment modification) and X (avoid combination) categories in the Lexi- Interact™ database were evaluated as pDDIs. SPSS analysis was performed. Results: A total of 54 asthma and 42 chronic obstructive pulmonary disease (COPD) patients were included in the study. Most asthma (76%) and COPD (83%) patients were found to have at least one comorbid disease. A total of81 pDDIs were identified in the Medscape database in asthma patients, and 86.5% of them were classified as “monitor closely”. A total of 12 drug interactions were detected in the Lexicomp database, with 75% of them were “D” category for asthma patients. In the prescriptions of COPD patients, a total of 162 drug interactions were determined via the Medscape database, with 94.4% classified as “monitor closely”. A total of 13 drug interactions were detected in the Lexicomp database, with 61.5% of them falling into the “X” category for COPD patients. Conclusions: According to the results of this study COPD patients who may be at a high risk of experiencing pDDIs. Healthcare providers should consider the individual patient’s clinical profile, including comorbidities and medication regimen, to minimize the risk of pDDIs and optimize treatment outcomes. Further research is needed to elucidate the mechanisms underlying these findings and develop tailored strategies to diminish the risks associated with pDDIs in respiratory disease management.